U.S approval of GlaxoSmithKline’s newest respiratory inhaler continues the global drugmaker’s shift from the blockbuster drug Advair to a suite of drugs that will be assembled at the British company’s Zebulon manufacturing site.
GSK said Thursday the company and business partner Theravance won approval from the Food and Drug Administration to market Breo Ellipta for asthma. The drug had been approved in 2013 for chronic obstructive pulmonary disease, but it failed to win approval for sale to minors as GSK officials had hoped.
{iframe}http://www.newsobserver.com/news/business/article20049951.html{/iframe}